For a more detailed discussion, please see Weiss 2001
The final model was subjected to comprehensive validation in MolProbity 37
WADA officially banned BPC-157 in early 2022
The candidate provided clinically meaningful weight loss, according to Novo, with the 11.8% weight reduction comparing to 2.3% in patients who received a placebo, in combination with lifestyle changes
Limited research has examined the effectiveness of these drugs, but L-carnitine, a type of supplement, may promote weight loss when combined with a balanced diet and regular exercise
The vast majority of the published literature on BPC-157 originates from the Zagreb consortium, with parallel work from collaborating groups in Croatia, China, and the United States